Daniella Beckman brings over 20 years of strategic, financial and operational experience to her role at Tango overseeing finance, investor relations and business development. Most recently, she has provided financial consulting for Tango since its inception, and prior to that, for another early-stage biotechnology company, Neon Therapeutics. Previously, Daniella was the Chief Financial Officer of Idenix Pharmaceuticals, where she oversaw finance, investor relations and IT until it was acquired by Merck in 2014. Prior to serving as Chief Financial Officer, Daniella served as corporate controller for Idenix. She previously held finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Daniella serves on the boards of directors of Vor Biopharma, and Blueprint Medicines.
Daniella has a Bachelor of Science degree in business administration/accounting from Boston University.